What's in Medtronic BRC's pipeline?

Medtronic BRC has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Medtronic BRC's portfolio?

Top competitors by shared drug class: Fundación EPIC, University of Parma.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/medtronic-brc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Medtronic BRC — Portfolio Competitive Intelligence Brief

Medtronic BRC pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Diuretic Increase (DI)	Diuretic Increase (DI)	marketed			Cardiovascular
Diuretic Suspension (DS)	Diuretic Suspension (DS)	marketed	Diuretic		Cardiovascular

Therapeutic area mix

Cardiovascular · 2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Fundación EPIC · 1 shared drug class
University of Parma · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Medtronic BRC:

Cite this brief

Drug Landscape (2026). Medtronic BRC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/medtronic-brc. Accessed 2026-05-16.